1. NOACs In Long-term VTE Treatment: A State Of The Art Review

3. Introduction

4. Most Common Causes of VTE

5. Burden of VTE

6. Burden of VTE in the European Union

7. Recurrent VTE After Discontinuation of Anticoagulation

8. Antithrombotic Therapy for VTE: CHEST Guideline and Expert Panel Report

9. VTE Treatment Phases

10. Risk Factors for Recurrence After a First VTE Event

11. Strategies for Preventing Recurrence of VTE

12. Strategies for Preventing Recurrence of VTE (cont)

13. Strategies for Preventing Recurrence of VTE (cont)

14. Risk Scoring Algorithms for VTE Recurrence[a]

15. Role of VTE Risk Stratification Tools

16. Conventional Treatment of VTE: Advantages and Disadvantages

17. Antithrombotic Therapy for VTE: CHEST Guideline and Expert Panel Report

18. Key Clinical Trials of NOACs in the Secondary Prevention of VTE

19. Advantages of NOACs vs Conventional Therapy in the Secondary Prevention of VTE

20. Potential Concerns Regarding the Use of NOACs in the Management of VTE

21. Variation in NOAC Administration Based on Methodologies of Phase III Studies

22. Reversal Agents Against NOACs

23. Considerations for Using NOACs vs VKA

24. Unanswered Questions Remain Regarding the Use of NOACs

25. Phase 3 Data for NOACs in the Extended Treatment of VTE

26. Hokusai-VTE: Edoxaban vs Warfarin for the Treatment of Symptomatic VTE

28. Extending NOAC Treatment for the Prevention of VTE: Clinical Perspectives

29. Extending NOAC Treatment for the Prevention of VTE: Clinical Perspectives (cont)

30. Conclusions

31. Abbreviations

32. Abbreviations